[
    [
        {
            "time": "2018-03-15",
            "original_text": "格隆汇港股聚焦(3.15)︱福耀玻璃2018年净利润升30.87%至41.2亿元 拟每10股派7.5元",
            "features": {
                "keywords": [
                    "福耀玻璃",
                    "净利润",
                    "增长",
                    "分红"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "汽车"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(3.15)︱福耀玻璃2018年净利润升30.87%至41.2亿元 拟每10股派7.5元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "渤海证券医药行业二季度投资策略报告：着眼精品，强者恒强",
            "features": {
                "keywords": [
                    "渤海证券",
                    "医药行业",
                    "投资策略",
                    "强者恒强"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "渤海证券医药行业二季度投资策略报告：着眼精品，强者恒强",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医疗保健：科创板利好科技创新型企业 荐15股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "科创板",
                    "科技创新",
                    "推荐股票"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗保健：科创板利好科技创新型企业 荐15股",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级] 医药生物-医保目录调整将至 继续深化“腾笼换鸟”",
            "features": {
                "keywords": [
                    "医药生物",
                    "医保目录",
                    "调整",
                    "腾笼换鸟"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[推荐评级] 医药生物-医保目录调整将至 继续深化“腾笼换鸟”",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "复星医药旗下生物类似药子公司复宏汉霖取得药品GMP证书",
            "features": {
                "keywords": [
                    "复星医药",
                    "生物类似药",
                    "复宏汉霖",
                    "GMP证书"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药旗下生物类似药子公司复宏汉霖取得药品GMP证书",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]